Comparison · NCT03667690-deaths
Group 1: Rezafungin for Injection vs Group 2: Caspofungin: deaths from any cause
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Group 1: Rezafungin for Injection vs Group 2: Caspofungin: deaths from any cause. Trial comparisons, record NCT03667690-deaths. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03667690-deaths
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.296 | 0.215 | 0.393 | wilson | |
| Risk in group 2 | 0.255 | 0.179 | 0.35 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0408 | -0.0838 | 0.164 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.16 | 0.735 | 1.83 | log | |
| Odds ratio, group 1 over group 2 | 1.23 | 0.655 | 2.3 | log | |
| Number needed to harm, for one more death from any cause on Group 1: Rezafungin for Injection than on Group 2: Caspofungin | 24.5 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Group 1: Rezafungin for Injection | Subjects in Rezafungin treatment group will receive a 400 mg loading dose in Week 1, followed by 200 mg once weekly, for a total of 2 to 4 doses.~Daily intravenous placebo infusions, when not administered Rezafungin and a daily placebo for oral step-down therapy (first eligibility on Day 4 or later as advised by a site's national/regional/local guidelines) administered every day.~Rezafungin for Injection: Intravenous antifungal therapy~oral placebo: Microcrystalline cellulose | 29 | 98 | EG000 |
| Group 2 | Group 2: Caspofungin | Subjects in caspofungin arm will receive a total treatment of ≥14 days beginning with a single caspofungin 70 mg IV loading dose on Day 1 followed by 50 mg IV once daily up to 28 days. After ≥3 days of caspofungin treatment(or the minimum duration of IV therapy advised by the site's national/regional/local guidelines, whichever is greater), subjects may be switched to oral fluconazole if specific parameters are met.~If the subject qualifies, then oral step-down therapy of fluconazole (6 mg/kg to the nearest 200 mg) is administered. After switch to oral step down before Day 8, subjects in the caspofungin group will receive IV placebo on Day 8 to preserve the study blind.~Caspofungin: Intravenous antifungal therapy~Fluconazole: Oral antifungal therapy~intravenous placebo: Normal saline | 25 | 98 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, all-cause mortality
- Time frame
Deaths and adverse events (AEs) were monitored and recorded from the time a subject signed the informed consent form (ICF) through the Follow-up visit (Days 52-59). Non-treatment-emergent adverse events were AEs occurring prior to dosing; treatment-emergent adverse events (TEAEs) were AEs that occurred during or at any time after dosing.
Source ClinicalTrials.gov
Trial
- Title
- Study of Rezafungin Compared to Caspofungin in Subjects With Candidemia and/or Invasive Candidiasis
- NCT number
- NCT03667690
- Phases
- PHASE3
- Conditions
- Candidemia, Mycoses, Fungal Infection, Invasive Candidiases
- Interventions
- Rezafungin for Injection, Caspofungin, Fluconazole, intravenous placebo, oral placebo
- Lead sponsor
- Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Results first posted
- 2023-01-06
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT03667690?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT03667690-deaths